About Arnivas 24 mg+26 mg Tablet
Arnivas is a tablet from Opsonin Pharma Ltd., with the generic name Sacubitril + Valsartan. Arnivas is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation for heart failure.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. 3 of them have a lower unit price than Arnivas. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is Arnivas 24 mg+26 mg Tablet?
Arnivas is a tablet from Opsonin Pharma Ltd., with the generic name Sacubitril + Valsartan. It helps lower the risk of cardiovascular death and hospitalization for heart failure. Do not start, stop, or change it without medical advice. Whether it suits you is a decision for your doctor.
Uses of Arnivas
Arnivas is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation for heart failure. It is a prescription medicine, and the doctor will confirm whether it is appropriate for the patient's condition. It is not a general heart tonic and is not meant for people without a heart failure diagnosis.
How to use Arnivas
Take Arnivas exactly as your doctor tells you. Arnivas is taken by mouth. Swallow the tablet with water. If you miss a dose, take it as soon as you remember, but skip it if it is almost time for the next dose. The dose and how often you take it will be decided by your doctor based on your condition and other medicines you take.
Side effects of Arnivas
The doctor will monitor you and decide if any change is needed. Your doctor may check your blood pressure, kidney function and potassium while you take this medicine. Some people may experience these effects. Tell your doctor if you feel very dizzy or faint, or pass much less urine than usual. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Use in pregnancy should be discussed with the doctor first, and children under one year are not covered. It is not recommended in severe liver impairment. It should not be taken with ACE inhibitors or with aliskiren in patients with diabetes. Tell your doctor about all the other medicines you take.
Frequently asked questions
What is Arnivas used for?
Arnivas is used in adults with chronic heart failure and reduced ejection fraction to lower the risk of cardiovascular death and hospitalisation for heart failure. It is a prescription medicine, and the doctor will confirm whether it is appropriate for the patient's condition.
How is Arnivas used?
Take Arnivas exactly as your doctor tells you. Arnivas is taken by mouth.
Can Arnivas cause side effects?
The doctor will monitor you and decide if any change is needed. Your doctor may check your blood pressure, kidney function and potassium while you take this medicine.
What is the price of Arnivas?
The listed price is ৳ 45.00.
- Strength
- 24 mg+26 mg
Price in Bangladesh
৳ 44.1 ৳ 45.00 2% off unit price
Price updated: 18 Nov 2026
Indications
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
... Read more
This is indicated:
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.
Dosage & Administration
Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.
Recommended Dose Titration-Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
Pediatric Patients At least 50 kg:
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
This combination is contraindicated:
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.
Pregnancy & Lactation
Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
See all 25 brands
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.